About this Course
This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.
Learning Objectives
Upon completion of this application based CE Activity, a pharmacist will be able to:
|
|
|
|
|
Release and Expiration Dates
Released: December 19, 2025
Expires: December 19, 2025
Course Fee
$17 Pharmacist
ACPE UAN
0009-0000-26-066-H05-P
Session Code
25RW66-DGB13
Accreditation Hours
1.0 hours of CE
Additional Information
How to Complete Evaluation: When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.
Accreditation Statement
| The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |  |
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-25-066-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
Grant Funding
There is no grant funding for this activity.
Faculty
C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
- Dr. White has no relationships with ineligible companies
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Content
Posttest
Patient Safety: Biosimilar Doppelgangers
25-066 Posttest
1. When a rituximab-arrx biosimilar is prescribed, how can you preempt the patient from falling victim to the nocebo effect?
a) Reinforce that biosimilars are inexpensive but equally effective and safe versions of the biologic they were taking
b) Go into the deep science and talk about tertiary protein folding difference but that they are not in the critical molecular areas
c) Tell them about how the deep state is out to get them and that taking a biosimilar leads to brainwashing impelled prescribing of 5G linked vaccines that makes people “Libtards”
*
2. You made the substitution to rituximab-arrx and three years go by with no issues. Then the efficacy starts to wane, and some flair ups occurs. What is the best course of action for the patient?
a) Switch back to the reference biologic rituximab
b) Switch to another biosimilar rituximab-pvvr
c) Switch to a biologic drug in another class
*
3. A patient has been successfully taking adalimumab-ryvk for a year now but, due to a supply chain issue, you do not have it in stock. Can you automatically substitute it for adalimumab-adbm?
a) You would look at the Purple Book and if one of them is an interchangeable biosimilar, the answer is yes
b) You can always automatically substitute a biosimilar to another biosimilar regardless if one is interchangeable or not
c) You are not allowed to automatically swap out one biosimilar for another even if they are both interchangeable with a reference (you need to call the prescriber and get a new prescription)
*
4. How is a biosimilar different from a generic drug?
a) A biosimilar is a small molecule product while generic drugs are large molecule
b) A biosimilar requires both immunogenicity assessments and pharmacodynamic assessments while generic drugs do not
c) A generic drug requires both immunogenicity assessments and pharmacodynamic assessments while biosimilars do not
*
5. Which of the following would not promote defining something as a biologic?
a) Expensive price
b) Monoclonal antibody
c) Made from living cells
*
6. Which of the following is true of an interchangeable biologic product vs. a biosimilar?
a) In all states, pharmacists can automatically substitute an interchangeable biologic product for an innovator product but would need a new prescription to dispense a biosimilar without interchangeable status.
b) Interchangeable biologic products are likely to have the same efficacy and safety as biosimilar products without interchangeable status.
c) The FDA is considering making interchangeable status harder to obtain by strengthening the evidence standards.
Handouts
VIDEO